Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

South Africa: Two Arrested in Tembisa Hospital Fraud Probe - South African News Briefs - November 17, 2026

[allAfrica]

Two more individuals have been apprehended in connection with the R635 million Tembisa Hospital corruption scandal, according to EWN. The suspects are alleged to have been involved in tender fraud, manipulating the hospital's procurement system by splitting transactions below the R500,000 limit. A third person was arrested in August as part of the investigation.

The Johannesburg High Court is currently hearing arguments over the detention of undocumented asylum seekers, following a Constitutional Court ruling that parts of the Refugee Act were found unconstitutional. Lawyers for the asylum seekers claim their continued detention is unlawful and they should be released and have their applications processed within 48 hours.

However, Home Affairs officials argue this timeframe is unfeasible due to a backlog of applications and have proposed a minimum 14-day detention period, assessed individually. Protesters in Johannesburg have caused traffic disruptions along Heidelberg Road in City Deep, with burning tyres and debris reported between Impex Avenue and Mpumelelo Road.

The Johannesburg Metropolitan Police Department has advised motorists to use alternative routes until the protest ends and the road is cleared.

Written by urgent.news from AllAfrica Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Other reports of this story

Every outlet that reported this, and when →

Read the original at allafrica.com →

More in Health & Medicine

Hanmi Drugs Show Promise in Phase 1 Trials

Hanmi Pharmaceutical said two next-generation anticancer drug candidates under development demonstrated both antitumor activity and safety in global Phase 1 clinical trials.

  • Hanmi's HM97662 and BH3120 showed promise in Phase 1 trials.
  • HM97662 targets EZH1 and EZH2 proteins to suppress gene expression.
  • BH3120 is an immuno-oncology candidate with positive liver toxicity results.

Novofactory Receives Flawless FDA Assessment

CG Bio, a regenerative medicine company, said its Novofactory facility in Hwaseong, Gyeonggi Province, concluded an on-site FDA inspection of human tissue operations with zero findings.

  • FDA gave CG Bio's Novofactory facility a flawless assessment in September.
  • Inspection covered quality management, donor verification, and traceability.
  • Novofactory set for completion in March will boost business and partnerships.

More from Tuesday 17 November →